Clinical Trials in Hangzhou, Zhejiang
1,519 recruiting
Showing 1–20 of 1,205 trials
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled174 locationsNCT07060807
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Kidney Disease
Takeda347 enrolled153 locationsNCT06963827
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC780 enrolled260 locationsNCT06312137
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled240 locationsNCT06459180
Recruiting
Phase 3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Essential Thrombocythemia
Merck Sharp & Dohme LLC300 enrolled167 locationsNCT06456346
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled205 locationsNCT05827081
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled380 locationsNCT05920356
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Endometrial Hyperplasia
Bayer207 enrolled86 locationsNCT06904274
Recruiting
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company406 enrolled288 locationsNCT06585787
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled109 locationsNCT04521231
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 2
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Bristol-Myers Squibb130 enrolled71 locationsNCT06855771
Recruiting
Phase 2
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd300 enrolled28 locationsNCT05686642